Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02465203 · ClinicalTrials.gov registry record · Phase 3
3-year Follow-up Study to Assess the Viral Activity in Hepatitis C Patients Who Failed Feeder DEB025/Alisporivir Study
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 105
- Enrollment target
NCT02465203 is a Phase 3 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 105 participants.
The verdict
NCT02465203, a Phase 3 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 105 participants
- Enrollment target
Study Summary
Follow-up for viral activity, changes in liver function and safety in patients with no SVR24 in feeder studies
Interventions
- DRUG Previous treatment in DEB025 study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2012-09-06 |
| Est. Completion | 2014-01-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02465203
The ClinicalTrials.gov registry entry for NCT02465203 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Previous treatment in DEB025 study is the first listed.
NCT02465203 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02465203 about?
NCT02465203 is a clinical study titled "3-year Follow-up Study to Assess the Viral Activity in Hepatitis C Patients Who Failed Feeder DEB025/Alisporivir Study". Follow-up for viral activity, changes in liver function and safety in patients with no SVR24 in feeder studies
What is the current status of trial NCT02465203?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 105 participants. The study started on 2012-09-06. Estimated completion is 2014-01-23.
What interventions are being tested in trial NCT02465203?
The interventions under investigation include: Previous treatment in DEB025 study (DRUG).
Who is sponsoring clinical trial NCT02465203?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.